Drug intelligence / Profile preview

levetiracetam + ketamine

Development stage: Preclinical
Lead developer: University of Virginia
Modality: Small Molecules
Administration: Intravenous

Overview

A drug combination used in the treatment of refractory status epilepticus. Ketamine acts on NMDA receptors while levetiracetam is an antiseizure medication that binds to the synaptic vesicle protein SV2A. When used together, they may have synergistic effects in controlling seizures, particularly in cases where conventional therapies have failed. However, this combination requires careful monitoring as it may increase the risk of side effects such as dizziness, drowsiness, confusion, and excessive sedation.

Targets

NMDAR (Glutamate receptor ionotropic, NMDA)

Beyond the preview

Go deeper on levetiracetam + ketamine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on levetiracetam + ketamine.

Explore the full profile